Singapore markets closed

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
53.83+2.83 (+5.55%)
At close: 03:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close51.00
Bid0.00 x 0
Ask0.00 x 0
Day's range53.49 - 53.99
52-week range49.70 - 86.31
Avg. volume98,829
Market cap39.987B
Beta (5Y monthly)0.59
PE ratio (TTM)13.18
EPS (TTM)4.09
Earnings dateN/A
Forward dividend & yield0.30 (0.60%)
Ex-dividend date09 May 2022
1y target est89.00
  • Reuters

    Lonza's full-year core EBITDA up 20.7% on vaccine demand

    (Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.

  • Motley Fool

    Should You Have Lonza Stock on Your Watchlist?

    In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.